Linna Zhang1, Saurabh Agarwal1, Jason M Shohet1, Peter E Zage2. 1. Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, U.S.A. 2. Department of Pediatrics, Section of Hematology-Oncology, Texas Children's Cancer and Hematology Centers, Baylor College of Medicine, Houston, TX, U.S.A. zage@bcm.edu.
Abstract
BACKGROUND/AIM: Melanoma tumor cell sub-populations expressing a variety of specific molecular markers have been identified. We hypothesized that expression of CD114, the cell surface receptor for granulocyte-colony stimulating factor (G-CSF), would be associated with melanoma tumor cell growth and response to treatment. MATERIALS AND METHODS: We determined the expression of CD114 expression in tumor cell lines by flow cytometry. We separated melanoma tumor cells into CD114-positive and - negative populations by fluorescence-activated cell sorting (FACS) and measured cell growth and responses to temozolomide and etoposide and the anticancer agent nifurtimox. RESULTS: All tested cell lines demonstrated a sub-population of cells with CD114 surface expression. CD114-positive sub-populations grew faster than CD114-negative ones and demonstrated resistance to temozolomide, etoposide, and nifurtimox. CONCLUSION: CD114 expression defines a sub-population of melanoma tumor cells with altered growth and resistance to treatment. Further studies on the role of CD114 in melanoma pathogenesis are warranted. Copyright
BACKGROUND/AIM: Melanoma tumor cell sub-populations expressing a variety of specific molecular markers have been identified. We hypothesized that expression of CD114, the cell surface receptor for granulocyte-colony stimulating factor (G-CSF), would be associated with melanoma tumor cell growth and response to treatment. MATERIALS AND METHODS: We determined the expression of CD114 expression in tumor cell lines by flow cytometry. We separated melanoma tumor cells into CD114-positive and - negative populations by fluorescence-activated cell sorting (FACS) and measured cell growth and responses to temozolomide and etoposide and the anticancer agent nifurtimox. RESULTS: All tested cell lines demonstrated a sub-population of cells with CD114 surface expression. CD114-positive sub-populations grew faster than CD114-negative ones and demonstrated resistance to temozolomide, etoposide, and nifurtimox. CONCLUSION:CD114 expression defines a sub-population of melanoma tumor cells with altered growth and resistance to treatment. Further studies on the role of CD114 in melanoma pathogenesis are warranted. Copyright
Authors: Megan Rose Paul; Yuchen Huo; Andrea Liu; Jacqueline Lesperance; Alexandra Garancher; Robert J Wechsler-Reya; Peter E Zage Journal: Neurooncol Adv Date: 2020-05-27
Authors: Irina V Kholodenko; Daniel V Kalinovsky; Igor I Doronin; Sergey M Deyev; Roman V Kholodenko Journal: J Immunol Res Date: 2018-07-11 Impact factor: 4.818
Authors: Jan Kučera; Karolína Strnadová; Barbora Dvořánková; Lukáš Lacina; Ivana Krajsová; Jiří Štork; Hana Kovářová; Helena Kupcová Skalníková; Petr Vodička; Jan Motlík; Pavel Dundr; Karel Smetana; Ondřej Kodet Journal: Oncol Rep Date: 2019-09-17 Impact factor: 3.906